Black Diamond Therapeutics, Inc. (BDTX) stock
BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.47−0.05 (-3.29%)
Close on Nov 13, 2026Market cap $84.46MP/E –Yield –
Black Diamond Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Black Diamond Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $27.67M, down 30.1% year over year. For fiscal 2025 it was $33.56M, down 34.6% from the year before. The highest annual figure on record is $96.83M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.56M | -34.6% |
| FY2024 | Dec 31, 2024 | $51.31M | -13.5% |
| FY2023 | Dec 31, 2023 | $59.35M | -7.9% |
| FY2022 | Dec 31, 2022 | $64.44M | -33.5% |
| FY2021 | Dec 31, 2021 | $96.83M | +100.9% |
| FY2020 | Dec 31, 2020 | $48.21M | +121.6% |
| FY2019 | Dec 31, 2019 | $21.75M | +213.0% |
| FY2018 | Dec 31, 2018 | $6.95M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $6.97M | -6.2% |
| Q2 FY2026 | Jun 30, 2026 | $7.39M | -20.7% |
| Q1 FY2026 | Mar 31, 2026 | $7.00M | -33.3% |
| Q4 FY2025 | Dec 31, 2025 | $6.30M | -48.8% |
| Q3 FY2025 | Sep 30, 2025 | $7.44M | -42.4% |
| Q2 FY2025 | Jun 30, 2025 | $9.32M | -25.8% |
| Q1 FY2025 | Mar 31, 2025 | $10.51M | -22.4% |
| Q4 FY2024 | Dec 31, 2024 | $12.30M | -19.6% |
| Q3 FY2024 | Sep 30, 2024 | $12.91M | -20.1% |
| Q2 FY2024 | Jun 30, 2024 | $12.56M | -4.5% |
| Q1 FY2024 | Mar 31, 2024 | $13.55M | -8.2% |
| Q4 FY2023 | Dec 31, 2023 | $15.29M | +4.7% |
| Q3 FY2023 | Sep 30, 2023 | $16.15M | +1.9% |
| Q2 FY2023 | Jun 30, 2023 | $13.15M | -18.8% |
| Q1 FY2023 | Mar 31, 2023 | $14.75M | -17.1% |
| Q4 FY2022 | Dec 31, 2022 | $14.61M | -25.7% |
| Q3 FY2022 | Sep 30, 2022 | $15.85M | -42.6% |
| Q2 FY2022 | Jun 30, 2022 | $16.20M | -39.4% |
| Q1 FY2022 | Mar 31, 2022 | $17.79M | -22.1% |
| Q4 FY2021 | Dec 31, 2021 | $19.66M | +10.7% |
| Q3 FY2021 | Sep 30, 2021 | $27.63M | +113.7% |
| Q2 FY2021 | Jun 30, 2021 | $26.72M | +162.7% |
| Q1 FY2021 | Mar 31, 2021 | $22.82M | +210.3% |
| Q4 FY2020 | Dec 31, 2020 | $17.76M | +138.0% |
| Q3 FY2020 | Sep 30, 2020 | $12.93M | +129.5% |
| Q2 FY2020 | Jun 30, 2020 | $10.17M | +80.1% |
| Q1 FY2020 | Mar 31, 2020 | $7.35M | +144.1% |
| Q4 FY2019 | Dec 31, 2019 | $7.46M | – |
| Q3 FY2019 | Sep 30, 2019 | $5.63M | – |
| Q2 FY2019 | Jun 30, 2019 | $5.65M | – |
| Q1 FY2019 | Mar 31, 2019 | $3.01M | – |
See a number that looks wrong?